NET ASSET VALUE – 31 July 2025
On the 31 July 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,164 million and NAV per share was SEK 53.33.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 453 | 5.81 | 10.9% |
| Xspray Pharma | 18% | 343 | 4.39 | 8.2% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 44% | 197 | 2.52 | 4.7% |
| KAHR Medical | 30% | 184 | 2.36 | 4.4% |
| Lipum | 57% | 171 | 2.19 | 4.1% |
| Xintela | 59% | 158 | 2.02 | 3.8% |
| Microbiotica | 10% | 129 | 1.65 | 3.1% |
| Mendus | 23% | 107 | 1.37 | 2.6% |
| Geneos Therapeutics | 12% | 94 | 1.20 | 2.2% |
| AnaCardio | 13% | 79 | 1.02 | 1.9% |
| Synerkine Pharma | 44% | 59 | 0.76 | 1.4% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.3% |
| Vitara Biomedical | 11% | 49 | 0.62 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.40 | 0.8% |
| Egetis Therapeutics | 1% | 31 | 0.39 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Toleranzia | 14% | 18 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.13 | 0.3% |
| Alder Therapeutics | 30% | 8 | 0.10 | 0.2% |
| Total | 2,418 | 30.98 | 58.1% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.59 | 4.8% |
| Symcel | 30% | 192 | 2.46 | 4.6% |
| Nanologica | 44% | 74 | 0.95 | 1.8% |
| Chromafora | 30% | 73 | 0.93 | 1.7% |
| Frontier Biosolutions | 2% | 18 | 0.24 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 576 | 7.38 | 13.8% | |
| Limited Partnerships, total | 107 | 1.37 | 2.6% | |
| Assets related to Portfolio companies | 293 | 3.75 | 7.0% | |
| Other assets and liabilities | 769 | 9.85 | 18.5% | |
| Net Asset Value | 4,164 | 53.33 | 100.0 | |